Controversies about iron in parkinsonian and control substantia nigra

Acta Neurobiologiae Experimentalis

Volumn 57, Issue 3, 1997, Pages 217-225

  Gała̧zka Friedman, Jolanta ^a   Friedman, Andrzej ^b  

^a WARSAW UNIVERSITY OF TECHNOLOGY   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Iron; Parkinson's disease; Substantia nigra

Indexed keywords

FERRITIN; HYDROCHLORIC ACID; HYDROXYL RADICAL; IRON; LIPID; NEUROMELANIN; PEPSIN A; PROTEIN;

ARTICLE; BINDING SITE; CELL DEATH; HISTOCHEMISTRY; HUMAN; LIPID PEROXIDATION; MICROANALYSIS; MOSSBAUER SPECTROSCOPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PARKINSON DISEASE; SPECTROPHOTOMETRY; SPECTROSCOPY; SUBSTANTIA NIGRA; X RAY FLUORESCENCE; X RAY MICROANALYSIS;

HUMANS; IRON; PARKINSON DISEASE; SUBSTANTIA NIGRA;

EID: 0030755867     PISSN: 00651400     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Antonini A., Leenders K.L., Meier D., Oertel W.H., Boesiger P., Anliker M. (1993) T2 relaxation time in patients with Parkinson's disease. Neurology 43: 697-700.
2. Barford N.C. (1987) Experimental measurements: precision, error and truth. John Wiley and Sons, Cichester, p. 76.
3. Bauminger E.R., Barcikowska M., Friedman A., Gała̧zka-Friedman J., Hechel D., Nowik I. (1994) Does iron play a role in Parkinson's disease? Hyperfine Interactions 91: 853-857.
4. Ben-Shachar D., Youdim M.B.H. (1992) Brain iron and nigrostriatal dopamine neurons in Parkinson's disease. In: Iron and human disease (Ed. R.B. Lauffer). CRC Press Inc. Boca Raton, p. 349-364.
5. Bizzi A., Brooks R.A., Brunetti A., Hill J.M., Alger J.R., Miletich R.S., Francavilla T.L., Di Chiaro G. (1990) Role of iron and ferritin in MR imaging of the brain: a study in primates at different field strenghts. Radiology 177: 59-65.
6. 2 values and iron levels. J. Neurol. Neurosurg. Psychiatry 52: 108-111.
7. Dexter D.T., Carter C.J., Wells F.R., Javoy-Agid F., Agid Y., Lees A., Jenner P., Marsden C.D. (1989a) Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J. Neurochem. 52: 381-389.
8. Dexter D.T., Wells F.R., Lees A.J., Agid F., Agid Y., Jenner P., Marsden C.D. (1989b) Increased nigral iron content and alterations in other metal ions occuring in brain in Parkinson's disease. J. Neurochem. 52: 1830-1836.
9. Drayer B.P., Olanow W., Burger P., Johnson G.A., Herfkens R., Riederer S. (1986) Parkinson plus syndrome: diagnosis using high field MR Imaging of brain iron. Radiology 159: 493-498.
10. Earle K.M. (1968) Studies on Parkinson's disease including X-ray fluorescent spectroscopy of formalin fixed brain tissue. J. Neuropathol. Exp. Neurol. 27: 1-14.
11. Fahn S., Cohen G. (1992).. The oxidant stress hypothesis in Parkinson's disease: evidences supporting it. Ann. Neurol. 32: 804-812.
12. Galazka-Friedman J., Bauminger E.R., Friedman A., Barcikowska M., Hechel D., Nowik I. (1996) Iron in parkinsonian and control substantia nigra - Mössbauer spectroscopy study. Movement Disorders 11: 8-16.
13. German B.B. (1995) Iron in CNS disease. J. Neuropathol. Exp. Neurol. 54: 477-486.
14. Gerlach M., Ben-Shachar D., Riederer P., Youdim M.B.H. (1994) Altered brain metabolism of iron as a cause of neurodegenerative diseases? J. Neurochem. 63: 793-807.
15. Gerlach M., Trautwein A.X., Zecca L., Youdim M.B.H., Riederer P. (1995) Mössbauer spectroscopic studies of purified human neuromelanin isolated from the substantia nigra. J. Neurochem. 65: 923-926.
16. Good P.F., Olanow C.W., Perl D.P. (1992) Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminium in Parkinson's disease: a LAMMA study Brain Res. 593: 343-346.
17. Gorell J.M., Ordidge R.J., Brown G.G., Deniau J-C., Buderer N.M., Helpern J.A. (1995) Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease. Neurology 45: 1138-1143.
18. Griffiths P.D., Crossman A.R. (1993) Distribution of iron in the basal ganglia and neocortex in postmortem tissue in Parkinson's disease and Alzheimer's disease. Dementia 4: 61-65.
19. Hallgren B., Sourander P. (1958) The effect of age on the non-haemin iron in the human brain. J. Neurochem. 3: 41-51.
20. Halliwell B. (1989) Oxidants and the central nervous system: some fundamental questions. Acta Neurol. Scand. 126: 23-33.
21. Halliwell B. (1992) Oxygen radicals as key mediators in neurological disease: fact or fiction? Ann. Neurol. 32: S10-S15.
22. Hirsch E.C., Brandel J.P., Galle P., Javoy-Agid F., Agid Y. (1991) Iron and aluminium increase in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis. J. Neurochem. 56: 446-451.
23. Jellinger K., Kienzl E. (1993) Iron deposits in brain disorders. In: Iron in central nervous system disorders (Eds. P. Riederer and M.B.H Youdim). Springer Verlag, Wien, p. 19-36.
24. Jellinger K., Kienzl E., Rumpelmair G., Riederer P., Stachelberger. H, Ben-Shachar D., Youdim M.B.H. (1992) Iron-melanin complex in substantia nigra of parkinsonian brains: an X-ray microanalysis. J. Neurochem. 59: 1168-1171.
25. Jellinger K., Paulus W., Grundke-Iqbal I., Riederer P., Youdim M.B.H. (1990) Brain iron and ferritin in Parkinson's and Alzheimer's diseases. J. Neural. Trans. [P-D Sect] 2: 327-340.
26. Lauffer R.B. (1992) (ed)- Iron and human disease. CRC Press Inc., Boca Raton, p. 534.
27. Loeffler D.A., Connor J.R., Juneau P.L., Snyder B.S., Kanaley L., DeMaggio A.J., Nguyen H., Brickman C.M., LeWitt P.A. (1995).. Transferrin and iron in normal, Alzheimer's disease, and Parkinson's disease brain regions. J. Neurochem. 65: 710-716.
28. Mann V.M., Cooper J.M., Daniel S.E., Srai K., Jenner O., Marsden C.D., Schapira A.H.V. (1994) Complex I, iron, and ferritin in Parkinson's disease substantia nigra. Ann. Neurol. 36: 876-881.
29. Riederer P., Sofic E., Rausch W.D., Schmidt B., Reynolds G.P., Jellinger K., Youdim M.B.H. (1989) Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J. Neurochem. 52: 515-520.
30. Riederer P., Youdim M.B.H. (1993) (eds)- Iron in central nervous system disorders. Springer-Verlag, Wien, p. 205.
31. Rutledge J.N., Hilal S.K., Silver A.J., Defendin R., Fahn S. (1987) Study of movement disorders and brain iron by MR. A.J.N.R. 8: 397-411.
32. Ryvlin P., Broussolle E., Piollet H., Viallet F., Khalfallah Y., Chazot G. (1995) Magnetic resonance imaging evidence of decreased putamental iron content in idiopathic Parkinson's disease. Arch. Neurol. 52: 583-588.
33. Schenck J.F., Mueller O.M., Souza S.P., Dumoulin C.L. (1990) Magnetic resonance imaging of brain using a 4 Tesla whole-body scanner. In: Iron biominerals (Eds. R.B. Frankel and R.P. Blakemore). Plenum Press, New York, p. 373-385.
34. Sofic E., Paulus W., Jellinger K., Riederer P., Youdim M.B.H. (1991) Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J. Neurochem. 56: 978-982.
35. Sofic E., Riederer P., Heinsen H., Beckmann H., Reynolds G.P., Hebenstreit G., Youdim M.B.H. (1988) Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J. Neural. Trans. 74: 199-205.
36. Spatz H. (1922) Uber den Eisennachweis in Gehirn, besonders in Zentren des extrapyramidal-motorischen Systems. Z. Ges. Neurol. Psychiat. 77: 261-390.
37. Uitti R.J., Rajput A.H., Rozdilsky B., Bickis M., Wollin T., Yuen W.K. (1989) Regional metal concentrations in Parkinson's disease, other chronic neurological diseases, and control brains. Can. J. Neurol. Sci. 16: 310-314.
38. Ye F.Q., Allen P.S., Martin W.R.W. (1996) Basal ganglia iron content in Parkinson's disease measured with magnetic resonance. Movement Disorders 11; 243-249.
39. Youdim M.B.H. (1994) Inorganic neurotoxins in neurodegenerative disorders without primary dementia. In: Neurodegenerative diseases. (Ed. Calne D.B.), W.B. Saunders Company, Philadelphia, p. 251-276.
40. Youdim M.B.H., Ben-Shachar D., Riederer P. (1989) Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration? Acta Neurol. Scand. 126: 47-54.
41. Youdim M.B.H., Ben-Shachar D., Riederer P. (1993) The possible role of iron in etiopathology of Parkinson's disease. Movement Disorders 8: 1-12.
42. Zecca L., Swartz H.M. (1993) Total and paramagnetic metals in human substantia nigra and its neuromelanin. J. Neural. Trans. [P-D Sect] 5: 203-213.
43. Zecca L., Shima T., Stroppolo A., Goj C., Battiston G.A., Gerbasi R., Sarna T., Swartz H.M. (1996) Interaction of neuromelanin and iron in substantia nigra and other areas of human brain. Neuroscience 73: 407-415.